We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Gottlieb Answers Senate Questions on Upholding FDA Standards

Gottlieb Answers Senate Questions on Upholding FDA Standards

FDA_Logo_Blue_2016.gif
April 11, 2017

FDA commissioner nominee Scott Gottlieb was grilled by a Senate panel over his financial ties to the industry he would be charged with regulating.

The April 5 hearing marked Gottlieb’s 19th time testifying before Congress on health care issues, and his experience showed.

He described how he would run the agency and address the challenges facing it, especially the opioid epidemic, and the cost of drug approvals.

“I believe in the gold standard for safety and effectiveness,” he said, responding to a question on Phase III clinical trials, before the Senate Health, Education, Labor and Pensions Committee.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 21Jun

    Medical Device Reporting: Best Practices and Common Pitfalls

  • 22Jun

    Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Linear Health Sciences Gets FDA Clearance for Its Orchid Safety Release Valve

  • Roche’s Faricimab Gains UK Approval Via International Program

  • Becton Dickinson Gets FDA Clearance for Its Molecular Diagnostic Platform

  • Bayer Backs Out of $670 Million Collaboration Deal With Atara

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing